BUZZ-KaloBios Pharmaceuticals Inc: Stops lung drug development
** Drug developer's shares down 60 pct at $0.74 after the bell
** Company drops experimental drug for lung infections after it failed mid-stage trial in cystic fibrosis patients
** Says drug, KB001-A, failed main goal of buying patients more time before taking antibiotics for worsening respiratory tract symptoms
** Up to Monday's close, stock had lost 44.4 pct since Jan. 30, 2014 when company stopped developing asthma drug
© Thomson Reuters 2017 All rights reserved.